• The US Food and Drug Administration (FDA) recently approved sunitinib malate (Sutent) capsules for two types of cancer: advanced renal cell carcinoma and malignant gastrointestinal stromal tumor (GIST), after disease progression on or intolerance to the frontline drug imatinib mesylate (Gleevec). (cancernetwork.com)
  • To determine the frequency and severity of adverse effects of Gleevec in this cohort of patients as assessed by CTC. (knowcancer.com)
  • Tasigna demonstrated that significantly fewer patients progressed to more advanced stages of the disease than the standard of care Gleevec (imatinib mesylate) tablets* at 12 months. (salesandmarketingnetwork.com)
  • All filings are based on data showing superior efficacy for Tasigna in the first head-to-head comparison of the drug against the standard of care Gleevec in newly diagnosed Ph+ CML patients. (salesandmarketingnetwork.com)
  • If approved for the first-line indication, Tasigna will be the first drug for newly diagnosed patients to become available since the approval of Gleevec in 2002. (salesandmarketingnetwork.com)
  • This randomized, open-label, multicenter trial compared the efficacy and safety of Tasigna versus Gleevec in adult patients with newly diagnosed Ph+ CML in chronic phase(1). (salesandmarketingnetwork.com)
  • In the ENESTnd clinical trial significantly fewer patients at 12 months progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Gleevec 400 mg once daily (2 patients vs. 11 patients)(1), demonstrating a significant improvement in disease control. (salesandmarketingnetwork.com)
  • Fewer patients discontinued due to adverse events from the Tasigna 300 mg twice daily arm of the study compared to the Gleevec 400 mg once daily arm. (salesandmarketingnetwork.com)
  • Tasigna has been approved in more than 80 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. (salesandmarketingnetwork.com)
  • Preclinical data shows improvements in response for the combination of imatinib mesylate (IM, Gleevec) and gemcitabine (GEM) therapy compared with GEM alone. (aacrjournals.org)
  • At the recent American Society of Clinical Oncology (ASCO) 2006 Gastrointestinal Cancers Symposium in San Francisco, researchers from Dana-Farber Cancer Institute in Boston reported on a phase III clinical trial in which sunitinib was given to control GIST in patients whose tumors had become resistant to imatinib. (cancernetwork.com)
  • These findings are highly significant because they show sunitinib can control tumors and improve survival rates of patients with this condition. (cancernetwork.com)
  • Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. (medscape.org)
  • Ulixertinib (BVD-523) is a highly potent, selective, and reversible ERK1/2 inhibitor and is currently in clinical development for the treatment of advanced solid tumors. (cp-456773inhibitor.com)
  • 148 Oct-3 is also overexpressed in a number of human germ cell tumors. (dnbforexpriceaction.com)
  • Imatinib is the first tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), and gastrointestinal stromal tumors (GIST) [ 1 ]. (e-crt.org)
  • Extending these promising findings to solid tumors faces substantial hurdles from drug uptake to clinical trial design. (aacrjournals.org)
  • In retrospect, the fact that cancer was viewed as a genetic disease for so long was likely an artifact of focus and technology: Chromosomal changes began to be detectable before we understood epigenetics at a molecular level, and the early focus on familial cancer and rapidly induced viral tumors favored the discovery of mutational carcinogenesis, which has largely colored our views over the past three decades ( 3, 4 ). (aacrjournals.org)
  • Access to imatinib has revolutionized the management of those tumors in our country. (biomedcentral.com)
  • Giant cell tumors (GCT) of the bone are aggressive and are recognised for variable clinical behaviour, which is not always related to radiographic or histological appearance [1]. (jbstjournal.com)
  • Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. (postersessiononline.eu)
  • Imatinib is a small molecule protein-tyrosine kinase inhibitor which is used for the treatment of leukemia and stomach tumors. (biopharmaservices.com)
  • A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) Jacksonville, Fla., Rochester, Minn. (mayo.edu)
  • A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study) Rochester, Minn. This study seeks adult subjects with R/R Ph+ B-precursor ALL. (mayo.edu)
  • Selumetinib in paediatric patients with BRAF -aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicenter, phase 2 trial. (medscape.org)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. (postersessiononline.eu)
  • Designing and Funding Clinical Trials of Novel Therapies, N Engl J Med 344:762-3, 2001 Antman K., Benson M. C., et al. (wikipedia.org)
  • The main aim for the future should be the careful design of clinical trials, by choosing the most clinically meaningful end-point and keeping in mind that combination of various agents may be more effective. (ersjournals.com)
  • There have been no randomized trials of sunitinib demonstrating clinical benefit such as increased survival or improvement in disease-related symptoms in renal cell carcinoma patients. (cancernetwork.com)
  • The regulatory submissions are based on data from the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients) Phase III clinical trial. (salesandmarketingnetwork.com)
  • The first clinical trials of Tasigna began 21 months after its discovery, with the drug receiving its first regulatory approval in the second-line indication in 2007(3). (salesandmarketingnetwork.com)
  • There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival. (salesandmarketingnetwork.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • A listing of 315 clinical trials in Delaware actively recruiting volunteers for paid trials and research studies in various therapeutic areas. (policylab.us)
  • Nationwide clinical trials offered in your area. (policylab.us)
  • PGP inhibitors are being developed to overcome multidrug resistance and two that have reached clinical trials are varapamil, a calcium channel blocker, and cyclosporin A, an immunosuppressant [7]. (savedelicious.com)
  • And, through clinical trials, researchers are looking for ways to improve current treatments as well as learn more about this blood cancer. (patientresource.com)
  • Adjuvant chemotherapy for localised resectable soft tissue sarcoma of adults: A meta-analysis of individual patient data. (wikipedia.org)
  • EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. (mayo.edu)
  • Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase CML in the tyrosine kinase inhibitor era (Ishida H et al. (cml-foundation.org)
  • Incomplete surgical resection leaves patients at increased risk for local recurrence and progression. (medscape.com)
  • Therefore, the identification of risk factors for imatinib-induced hepatotoxicity could reduce the occurrence of hepatotoxicity, thereby preventing progression to chronic liver disease and/or acute liver failure. (e-crt.org)
  • They can also cause base mispairing between strands, which interferes with the progression of the replication fork [3]. (savedelicious.com)
  • this introduces a resource that should gain relevance considering the increasing number of oral anticancer drugs. (ons.org)
  • Classification of anticancer drugs 3. (present5.com)
  • 8-13 Tyrosine kinase inhibitors (TKI) (imatinib, sunitinib, and regorafenib) have dramatically changed the treatment landscape and outcomes for gastrointestinal stromal tumour (GIST), one of the most common STS subtypes. (emjreviews.com)
  • This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. (mayo.edu)
  • This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. (ucsf.edu)
  • Originally called SU11248, sunitinib is an oral therapy belonging to a new class of multikinase inhibitors that attack cancer by inhibiting both tumor growth and blood supply. (cancernetwork.com)
  • In the study, the research team led by Dr. Demetri compared overall survival and duration of tumor control in two groups of imatinib-resistant GIST patients-207 received sunitinib, and 105 received a placebo. (cancernetwork.com)
  • Sunitinib-treated patients also had a 50% reduction in the relative risk of death compared to their counterparts. (cancernetwork.com)
  • The benefits of sunitinib held steady regardless of the dose or duration of imatinib therapy that patients previously had received. (cancernetwork.com)
  • Sunitinib was generally well tolerated, with side effects such as mild to moderate fatigue, diarrhea, nausea, mouth sores, and skin discoloration, which rarely interfered with the patients' ability to continue taking the drug. (cancernetwork.com)
  • The results were so striking, even at the first interim data analysis, that the independent data-monitoring committee recommended that patients initially assigned to the placebo group be allowed to take sunitinib, said Dr. Demetri. (cancernetwork.com)
  • This is a descriptive cross-sectional study, with retrospective data collection over a 10-year period from 2010 to 2020, focused on patients with histological confirmed gastro-intestinal stromal tumor (GIST). (biomedcentral.com)
  • The availability of imatinib has improved the outcome of GIST with response in all cases it was used in neoadjuvant setting ( n = 7). (biomedcentral.com)
  • It is the only one capable of ensuring the continuum of care for patients with GIST (availability of imatinib and digestive surgical oncology). (biomedcentral.com)
  • Our aim is to describe the diagnosis, therapeutic management, and outcome of GIST since the availability of imatinib in our country. (biomedcentral.com)
  • We included medical reports of all patients having the definitive diagnosis of GIST with a histological and immunohistochemical proof. (biomedcentral.com)
  • Phase II study of high dose cyclophosphamide, thiotepa, & carboplatin with autologous marrow support in measurable advanced breast cancer responding to standard dose therapy. (wikipedia.org)
  • A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL Rochester, Minn., Jacksonville, Fla. (mayo.edu)
  • The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • The results of one study 7 showed elevated levels of human herpesvirus 7 in patients with pityriasis rosea. (aafp.org)
  • However, subsequent study results 6 , 8 , 9 showed no consistent increase of human herpesvirus 7 levels in affected patients compared with control patients. (aafp.org)
  • However, the results of a small prospective case-control study 10 did not show a significant rise in antibodies to these bacteria when affected patients were compared with matched control patients. (aafp.org)
  • However, no randomized or nonrandomized study using 3 months of NADT has shown any statistically significant benefit in terms of overall and disease-free survival. (medscape.com)
  • No patients in the study had a prolongation of the QT interval >500 milliseconds(1). (salesandmarketingnetwork.com)
  • A phase 1 study of AZD6244 in children with recurrent or refractory low grade gliomas: a pediatric brain tumor consortium report. (medscape.org)
  • A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. (medscape.org)
  • Phase II study of binimetinib in children and adults with NF1 plexiform neurofibromas (NF108-BINI). (medscape.org)
  • A study of the drugs selumetinib verus carboplatin/vincristine in patients with neurofibromatosis and low-grade glioma. (medscape.org)
  • Trametinib in pediatric patients with neurofibromatosis type 1-associated plexiform neurofibroma: a phase I/II study. (medscape.org)
  • The purpose of the study is to evaluate how safe and effective an investigational study drug is compared to a placebo (both groups will receive injections, but the placebo contains no active medication) in the treatment of liver disease. (policylab.us)
  • The purpose of this study was to investigate factors affecting on the incidence of hepatotoxicity within 90 days after starting imatinib treatment and time to onset of imatinib-induced hepatotoxicity. (e-crt.org)
  • The findings of this study suggest that the use of PPIs and presence of liver disease or HBV were associated with imatinib-induced hepatotoxicity. (e-crt.org)
  • In addition, another study showed that the latency to onset of hepatic injury by imatinib was 12 to 77 days [ 11 ]. (e-crt.org)
  • Several medications and therapies are in the very early phases of study for scleroderma. (mountsinai.org)
  • The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion). (ucsf.edu)
  • The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month. (ucsf.edu)
  • ObjectiveTo study the pharmacokinetics difference of levofloxacin polymorphs in rats, evaluate the advantageous medical polymorph, and explore the effects of different polymorphs on clinical medicine.MethodsFour crystal forms of levofloxacin were administered intragastrically to rats,and high performance liquid chromatography (HPLC) was used to measure the contents of levofloxacin in rat plasma. (yydbzz.com)
  • This is a retrospective study conducted in 5 consecutive patients of GCT of distal radius. (jbstjournal.com)
  • Informed consent from the patient was taken and approval from the institutional review board was obtained for the study. (jbstjournal.com)
  • The Food and Drug Agency (FDA) product-specific guidance for bioequivalence (BE) assessment of imatinib mesylate recommends study strength/dose of 400 mg in patients who are already receiving a stable 400 mg dose, rather than normal healthy volunteers (NHV). (biopharmaservices.com)
  • In contrast to the FDA, the European Medicines Agency (EMA) has recently issued a product specific Bioequivalence guidance on imatinib recommending the use of NHV as the study population. (biopharmaservices.com)
  • BE study of imatinib to be done in patients already receiving the 400 mg imatinib recommended by FDA was mostly due to the safety consideration. (biopharmaservices.com)
  • Our large experience with imatinib demonstrated that a single oral dose of 400 mg of imatinib in a two-way crossover study with NHV is safe and appropriate bioequivalence study design for for submissions indented for all regulatory agencies including the US FDA. (biopharmaservices.com)
  • When oral TKIs were introduced, given all their benefits, high adherence rates were a foregone conclusion. (ons.org)
  • With gene-wise functional analyses, we detected a significant correlation between recurrent NOTCH2 noncoding mutations and clinical response to imatinib. (e-crt.org)
  • For participants who cannot swallow tablets or who are receiving less than a 10 mg dose, a capsule with small ponatinib minitablets inside will be provided. (ucsf.edu)
  • Tenax Therapeutics is developing novel dosing and a unique formulation of imatinib mesylate, a kinase inhibitor that has received FDA's orphan designation (March 2020) for the treatment of pulmonary arterial hypertension (PAH). (biospace.com)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • Tasigna is a potent and selective inhibitor of the Bcr-Abl protein that causes production of cancer cells in Ph+ CML(2,3). (salesandmarketingnetwork.com)
  • JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH) ( 1 ). (drugs.com)
  • The median survival from the time of diagnosis is 3 years and this explains why IPF is currently considered more lethal than many cancers [ 2 ]. (ersjournals.com)
  • The diagnosis was neuroectodermal embryonal tumor with patterns of ME (Table 1 , Figure 2 and Figure 3 ). (biomedcentral.com)
  • Prescribe JUXTAPID only to patients with a clinical or laboratory diagnosis consistent with HoFH. (drugs.com)
  • Some drugs, such as rituximab (Rituxan), mycophenolate mofetil (CellCept), and imatinib mesylate (Gleevac), used to treat certain autoimmune diseases and cancers may play a role in treating scleroderma. (mountsinai.org)
  • Some are specifically approved for newly diagnosed patients, while others are approved for use after other therapies have failed due to resistance, changes in mutations or intolerance. (patientresource.com)
  • Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the underlying mechanism of and factors influencing imatinib-induced hepatotoxicity have rarely been investigated. (e-crt.org)
  • Hepatotoxicity of imatinib could aggravate the patient's clinical condition and alter the patient's treatment plan. (e-crt.org)
  • Hematopoietic stem cell transplantation remains the only curative therapeutic approach that reliably results in resolution of bone marrow fibrosis in patients with myelofibrosis. (haematologica.org)
  • Various therapeutic options, including imatinib, are available to treat desmoid tumor. (e-crt.org)
  • Our results show that HES1 , regulated by NOTCH2 , as an indicator of sensitivity to imatinib, and an important therapeutic consideration for desmoid tumor. (e-crt.org)
  • Imatinib acts on underlying cellular proliferative pathways associated with PAH and has the potential to be the first disease modifying therapy for PAH. (biospace.com)
  • RP is most likely to cure patients with organ-confined disease. (medscape.com)
  • Patients with liver disease or hepatitis B virus (HBV) carriers had a more than 8-fold higher risk of hepatotoxicity and a 5.2-fold increased hazard of hepatotoxicity compared to those without liver disease or HBV. (e-crt.org)
  • Indicated for treatment of Ph-negative ALL for patients in second or greater relapse or whose disease has progressed following 2 or more antileukemia therapies. (medscape.com)
  • Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposition of reticulin and collagen fibrosis in the bone marrow of patients with myelofibrosis is believed to be mediated by the myelofibrosis hematopoietic stem/progenitor cell, contributing to an impaired microenvironment favoring malignant over normal hematopoiesis. (haematologica.org)
  • 5 4 In addition to increased disease-related morbidity, MF results in early death with the median survival of affected patients being approximately 6 years. (haematologica.org)
  • Among 20 patients, four (20%) had a partial response and 14 (66.7%) had stable disease, 11 of which continued for ≥ 1 year. (e-crt.org)
  • To develop the most appropriate disease management plan for you, your doctor will take into consideration the phase of the CML, the presence of chromosome abnormalities and your general health. (patientresource.com)
  • Patients with end-stage renal disease on dialysis or with baseline mild hepatic impairment should not exceed 40 mg daily ( 2.5 , 2.6 ). (drugs.com)
  • It is the largest global randomized comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients. (salesandmarketingnetwork.com)
  • To estimate the clinical response rate (partial and complete response as defined under the RECIST criteria). (knowcancer.com)
  • Here, we describe potential roles of NOTCH2 and HES1 in clinical response to imatinib at genome and transcriptome levels. (e-crt.org)
  • RNA-sequencing was performed using prospective and retrospective cohort samples to evaluate the expressional relevance with clinical response. (e-crt.org)
  • Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicentre experience in Taiwan (Liu HC et al. (cml-foundation.org)
  • Results of Tenax Therapeutics' Phase 2 trial of levosimendan in patients with pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) demonstrated that IV levosimendan produces potent dilation of the central and pulmonary venous circulations which translates into an improvement in exercise capacity, a discovery that forms the basis for the Phase 3 investigation of Tenax Therapeutics' potential groundbreaking therapy. (biospace.com)
  • A041501, A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL Rochester, Minn. (mayo.edu)
  • However, the NCCN notes that androgen deprivation therapy before, during, and/or after radiation prolongs survival in selected patients who are receiving radiation therapy only. (medscape.com)
  • 2011). Even for patients showing resistance to first-line therapy, their life expectancy may improve because of modern TKI alternatives (Kantarjian et al. (ons.org)
  • Antineoplastic agents are used for induction, consolidation, and maintenance therapy and central nervous system (CNS) prophylaxis in patients with acute lymphoblastic leukemia (ALL). (medscape.com)
  • We do not know yet how to select patients for this therapy and how to move it from life extension to cure. (aacrjournals.org)
  • Walking with patients through this journey from start to finish, and offering therapy and guidance along the way, is a source of professional and personal satisfaction for me. (rochester.edu)
  • Some targeted therapy drugs are oral medications given in pill form, and others are given intravenously (IV). (patientresource.com)
  • Targeted therapy , given orally in pill form, is often the first line of treatment for chronic phase CML. (patientresource.com)
  • however, some patients in the chronic phase can receive targeted therapy and remain in remission for many years. (patientresource.com)
  • Imatinib, an oral targeted therapy, has been available in Benin since 2010 and free since 2016. (biomedcentral.com)
  • Four weeks later, clinical and radiographic assessments were performed to evaluate soft tissue inflammation and bone resorption level. (bvsalud.org)
  • Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (Nishiyam-Fujita Y et al. (cml-foundation.org)
  • We retrospectively evaluated the records of 177 patients receiving imatinib from October 2012 to September 2017. (e-crt.org)
  • During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. (ersjournals.com)
  • Hematology/oncology is a field where clinical and basic research can be rapidly applied to improve outcomes and quality of life. (rochester.edu)
  • Most cancer chemotherapeutic drugs affect only one characteristic aspect, which is uncontrolled proliferation [3]. (savedelicious.com)
  • When patients develop resistance, multiple drugs with different pathways of entry and different cellular targets are used. (savedelicious.com)
  • However, owing to the inaccuracy of clinical staging, approximately 50% of men with clinical stage T1 or T2 prostate cancer have tumor extension outside of the prostate capsule, and 5-40% have positive surgical margins. (medscape.com)
  • These cells not only demonstrated a 3-foldincrease in resistance to doxorubicin and a 9-fold increase in resistance to paclitaxel, but also showed increased efflux of rhodamine. (sphingolipidclub.com)
  • this population of patients has yet to be defined, but its parameters may become clearer as the optimal duration and form of NADT is defined. (medscape.com)
  • EAST HANOVER, N.J., Feb. 19 -- (Healthcare Sales & Marketing Network) -- Novartis announced today that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (salesandmarketingnetwork.com)
  • Now this priority review designation brings us one step closer to offering patients who are newly diagnosed with Ph+ CML in the chronic phase a promising new treatment option. (salesandmarketingnetwork.com)
  • In patients with clinically localized prostate cancer, the National Comprehensive Cancer Network (NCCN) strongly discourages the use of NADT before RP outside of a clinical trial. (medscape.com)
  • However, one critical mechanism of MDR is related to ATP-binding cassette (ABC) transporters, which are located on the membrane of cancer cells [3]. (cp-456773inhibitor.com)
  • 3 ] Ocular melanoma is the most common cancer of the eye, with approximately 2,000 cases diagnosed annually. (cancer.gov)
  • When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. (rochester.edu)
  • American Cancer Society Clinical Fellowship Award. (rochester.edu)
  • This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). (ucsf.edu)
  • Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group (Kodama Y et al. (cml-foundation.org)
  • Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens. (ucsf.edu)
  • Its mechanism of action involves preventing the phosphorylation of the cell cycle-regulating substrate by occupying the adenosine triphosphate-binding site of several tyrosine kinase molecules including Bcr-Abl, c-KIT, and platelet-derived growth factor receptors (PDGFRα and PDGFRβ) [ 2 , 3 ]. (e-crt.org)
  • However, the molecular mechanism of why imatinib works remains unclear. (e-crt.org)
  • In at least one half of patients, the first symptoms of pityriasis rosea are nonspecific and consistent with a viral upper respiratory infection. (aafp.org)
  • 4 Second, recurrence of pityriasis rosea outside the acute phase is rare, suggesting that there is long-lasting immunity after the infection. (aafp.org)
  • 2014). As early as 2001, scientists proposed focusing more on patients' perceptions and favored qualitative studies to understand this (Verbrugghe, Duprez, et al. (ons.org)
  • 2001;74(1-3):31-46. (springer.com)
  • Tenax Therapeutics has North American rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. (biospace.com)
  • According to this system, 2 tumours were classified as Stage I and 3 tumours as Stage II. (jbstjournal.com)
  • Once the patient was medically fit, surgery (ORIF with resection of distal end of radius and reconstruction with ipsilateral non vascularised proximal fibula along with plate and 2 k-wires) was performed. (jbstjournal.com)
  • The IMPRES trial, a previous Phase 3 trial, demonstrated that oral imatinib may produce a markedly greater, and much more durable, treatment effect on exercise tolerance, than any other available PAH treatment, alone or in combination, based on the results observed in those patients who were maintained on the full imatinib dose for the majority of the trial. (biospace.com)
  • Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. (medscape.org)
  • The maximum plasma imatinib concentration was reached from 1 and 5 hrs, and the half-life was in the range of 10 to 19 hrs, consistent with reported information from the literature using lower strengths. (biopharmaservices.com)
  • 3 Myelofibrosis (MF) refers to the Philadelphia chromosome ( BCR-ABL1 )-negative myeloproliferative neoplasm (MPN) originating at the level of the multipotent hematopoietic stem cell. (haematologica.org)
  • Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia (Schleicher O et al. (cml-foundation.org)
  • Oncology nurses may help provide tailored support, thereby ameliorating care for these patients. (ons.org)
  • Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. (springer.com)
  • Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients with B-ALL. (ucsf.edu)
  • 0075(3, provided L is rich enough to contain every symbol of the programs and queries under consideration. (dnbforexpriceaction.com)
  • All eligible subjects received a single oral dose of 400 mg of both test and reference products on separate occasions with 2 weeks of washout. (biopharmaservices.com)
  • Antman's publications also include reviews and editorials on medical policy and the impact of research funding and managed care on American clinical research. (wikipedia.org)